You are here

Automated Preferential Display for the Analysis of Gene Expression Profiles

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: DAAD13-02-P-0039
Agency Tracking Number: C021-0020
Amount: $69,900.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
PO Box 200759
Austin, TX 78729
United States
DUNS: 807519264
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Robert Chin
 President
 (512) 659-4539
 rchin@genexpressinfo.com
Business Contact
 Ricky Virgne
Title: CFO
Phone: (512) 990-1200
Email: rvigne@swbell.net
Research Institution
N/A
Abstract

"GeneXpress Informatics, Inc. (GXI) and Dr. James P. Chambers of UTSA propose to develop a revolutionary differential gene display technology, called Preferential Display (PD) which will provide for a simplified, cost-effective method to identify thesegenes for use in discovering gene expression profiles without having any prior knowledge of an organism, tissue or biological samples' genome. The technology utilizes a combination of biomolecular chemistry methods to eliminate redundant sequences andfluorescence dye assay to identify and isolate these unique sequences.In Phase I, GXI and Dr. Chambers propose to develop and demonstrate the PD technology by identifying unique gene sequences expressed by different cell or tissue types. In Phase II, GXI will develop PD benchtop high throughput system for rapid isolationand identification of unique gene expression profiles. Also included in the Phase II will be a lab-on-chip implementation of the PD technology for a future handheld biosensor application. GXI's Preferential Display is a breakthrough technology which is used to identify unique gene expression sequences of these cellular changes thus providing potentially new age related drug targets to pharmaceutical company end users."

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government